Citius Pharmaceuticals is trading 5% down at $0.57 as investors weigh Nasdaq’s extension requiring the company to regain the $1.00 minimum bid price by February 8, 2027.
- Failure to meet the requirement could lead to delisting proceedings, highlighting ongoing listing risk.
- The decline follows sharp recent volatility, including the August 17 selloff.
- Major indexes were broadly mixed, and no new major company announcement or broad-market catalyst was identified for August 24, 2026.